首页> 外文期刊>Journal of Breast Cancer >Clinicopathologic factor and Lymphovascular Invasion in Breast cancer
【24h】

Clinicopathologic factor and Lymphovascular Invasion in Breast cancer

机译:乳腺癌的临床病理因素和淋巴血管浸润

获取原文
       

摘要

Purpose Clinicopathologic factors associated with prognosis in breast cancer patients have varied. Among clinicopathologic factors, lymphovascular invasion (LVI) has been suggested to be a significant prognostic indicator for breast cancer. LVI means that cancer cells were found invading the lymphatics in the breast parenchyma adjacent to or well beyond the margin of the invasive tumor, and this can be an indicator of an increased chance that cancer could spread, as is demonstrated by the positive lymph nodes. The objective of this study was to determine whether LVI are associated with other clinicopathologic factors in breast cancer. Methods The expression of HER-2, Ki-67, P53, estrogen receptor and progesterone receptor was determined immunohistochemically in 120 breast cancer patients, including 77 patients that demonstrated the absent of LVI and 43 patients with the present of LVI. Results LVI was noted in 43 patients (35.8%) of the 120 breast cancer patients. Of the 77 patients with absent of LVI, the number of stage III patients (13 patients, 16.9%) was lower than the number of stage I (25 patients, 32.5%) and stage II breast cancer patients (39 patients, 50.6%). Of the 43 patients with absent of LVI, 5 patients (11.6%), 13 patients (30.2%), and 25 patients (58.2%) were in stage I, II, and III, respectively. There was a significant correlation between LVI and the stage ( P =0.000). The strong expression (+3) of HER-2 was seen in 17 (39.5%) of the 43 patients in whom LVI was seen and in 15 (19.5%) of the 77 patients in whom LVI was not seen. Overexpression of Ki-67 was noted in 42 (97.7%) of the 43 patients in whom LVI was seen and in 64 (83.1%) of the 77 in whom LVI was not seen. HER-2 and Ki-67 overexpression was significantly associated with LVI ( p =0.027 and p =0.018, respectively). LVI did not correlate with the expression of P53, the estrogen receptor status and the progesterone receptor status. There was a strong association of LVI and the lymph node status ( p =0.000). Finally, LVI was associated with tumor size ( p =0.014) and with the nuclear grade ( p =0.022). Conclusion This study demonstrates the potential value of the lymph nodal status, tumor size, stage and nuclear grade for the assessment of lympho-vascular invasion; and the overexpressions of HER-2 and Ki-67 were strong indicators of LVI in invasive ductal carcinoma of the breast.
机译:目的与乳腺癌患者预后相关的临床病理因素多种多样。在临床病理因素中,淋巴管浸润(LVI)被认为是乳腺癌的重要预后指标。 LVI意味着发现癌细胞侵袭了浸润性肿瘤边缘附近或远远超出浸润性肿瘤边缘的乳腺实质中的淋巴管,这可以表明癌症扩散的机会增加,如阳性淋巴结所示。这项研究的目的是确定LVI是否与乳腺癌的其他临床病理因素有关。方法采用免疫组织化学方法检测120例乳腺癌患者中HER-2,Ki-67,P53,雌激素受体和孕激素受体的表达,其中77例表现为LVI缺失,43例表现为LVI。结果120例乳腺癌患者中有43例(35.8%)出现LVI。在77例缺乏LVI的患者中,III期患者(13例,占16.9%)低于I期患者(25例,占32.5%)和II期乳腺癌患者(39例,占50.6%)。 。在IVI期缺席的43例患者中,分别处于I,II和III期的5例患者(11.6%),13例患者(30.2%)和25例患者(58.2%)。 LVI与阶段之间存在显着相关性(P = 0.000)。在43例LVI患者中有17例(39.5%)和在77例LVI患者中没有15例(19.5%)观察到HER-2的强表达(+3)。观察到43例LVI患者中有42例(97.7%)和未观察到LVI 77例中64例(83.1%)注意到Ki-67过表达。 HER-2和Ki-67过表达与LVI显着相关(分别为p = 0.027和p = 0.018)。 LVI与P53的表达,雌激素受体状态和孕激素受体状态无关。 LVI与淋巴结状态密切相关(p = 0.000)。最后,LVI与肿瘤大小(p = 0.014)和核分级有关(p = 0.022)。结论本研究表明淋巴结状态,肿瘤大小,分期和核分级对评估淋巴管浸润的潜在价值。 HER-2和Ki-67的过度表达是乳腺浸润性导管癌中LVI的重要指标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号